SciClone Announces Enrollment Completion In Phase 2 Oral Mucositis Trial Of SCV-07

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that patient enrollment is complete ahead of schedule for its phase 2 trial of SCV-07 a small molecule synthetic peptide with immunomodulating properties for the treatment of severe oral mucositis (OM) in patients with head and neck cancer. Topline results of the oral mucositis trial are expected to be announced in the first half of 2010.

source : www.medicalnewstoday.com

Related News:

• Inspire Announces Results From AZASITE(R) Phase 2 Blepharitis Trials And Plans To Continue Clinical Development In Anterior And Posterior Blepharitis
• ACC: FDA Announces Review of ACCORD Data
• ETEX Corporation Announces FDA Clearance And Launch Of Carrigen(R) Porous Bone Substitute Material
• Graceway Announces Journal Of The American Academy Of Dermatology Publishes Articles On New Short-Course Imiquimod Formulation In Actinic Keratosis
• Auxilium Announces Availability Of XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• NPS Pharmaceuticals Announces Support For Rare Disease Day Observance
• Health Ranger announces "Healing Miracles LIVE" event in Southern Calif., March 19 – 20, with Horowitz, Whitaker, Gerson and more
• Cytokinetics Announces Non-Clinical Data From Multiple Programs To Be Presented At The Biophysical Society 54th Annual Meeting
• Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones And The Initiation Of A Clinical Trial Of Ecopipam In Lesch-Nyhan Disease
• Merz Pharma Announces Launch Of Denzapine As First Available Generic For Treatment-Resistant Schizophrenia